Einzeltreffer — DigiBib

Objective: To analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.

Design: Descriptive and retrospective observational study.

Material and Methods: The pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).

Results: The mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.

Conclusions: The application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.

Titel:	[New tools for medication review: DRP in patients treatment with proton pump inhibitors].
Autor/in / Beteiligte Person:	Gutiérrez-Igual, S ; Lucas-Domínguez, R ; Martí Rodrigo, A ; Romero Crespo, I ; Montesinos Mezquita, MC
Zeitschrift:	Atencion primaria, Jg. 56 (2024-05-01), Heft 5, S. 102836
Veröffentlichung:	Madrid : Elsevier España ; <i>Original Publication</i>: Barcelona : Haymarket,, 2024
Medientyp:	academicJournal
ISSN:	1578-1275 (electronic)
DOI:	10.1016/j.aprim.2023.102836
Schlagwort:	Humans Female Male Retrospective Studies Aged, 80 and over Aged Middle Aged Drug-Related Side Effects and Adverse Reactions epidemiology Proton Pump Inhibitors therapeutic use
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: Spanish; Castilian Transliterated Title: Nuevas herramientas para la revisión de la medicación: PRM en pacientes en tratamiento con inhibidores de la bomba de protones. Publication Type: Journal Article; Observational Study; English Abstract Language: Spanish; Castilian [Aten Primaria] 2024 May; Vol. 56 (5), pp. 102836. <i>Date of Electronic Publication: </i>2023 Dec 26. MeSH Terms: Proton Pump Inhibitors* / therapeutic use ; Humans ; Female ; Male ; Retrospective Studies ; Aged, 80 and over ; Aged ; Middle Aged ; Drug-Related Side Effects and Adverse Reactions / epidemiology References: Aust J Gen Pract. 2022 Nov;51(11):845-848. (PMID: 36310001) ; Int J Clin Pharm. 2014 Jun;36(3):630-5. (PMID: 24736895) ; CMAJ Open. 2023 Feb 28;11(1):E170-E178. (PMID: 36854455) ; Pharmacoepidemiol Drug Saf. 2020 Apr;29(4):433-443. (PMID: 31908111) ; Semergen. 2022 Apr;48(3):163-173. (PMID: 35151557) ; Int J Clin Pharm. 2018 Oct;40(5):1199-1208. (PMID: 30073611) ; J Clin Pharm Ther. 2007 Oct;32(5):469-76. (PMID: 17875113) ; Int J Clin Pharm. 2022 Aug;44(4):914-921. (PMID: 35449351) ; Int J Clin Pharm. 2023 Jun;45(3):650-658. (PMID: 36862254) ; Int J Clin Pharm. 2011 Dec;33(6):1010-8. (PMID: 22081243) ; J Pharm Pract. 2020 Oct;33(5):661-665. (PMID: 30791857) ; PLoS One. 2012;7(3):e33236. (PMID: 22438900) ; Eur J Clin Pharmacol. 2015 Oct;71(10):1255-62. (PMID: 26249851) ; Aten Primaria. 2017 Mar;49(3):166-176. (PMID: 27693033) ; Pharmazie. 2016 Sep 1;71(9):548-551. (PMID: 29441854) ; BMJ. 2022 Oct 24;379:e069211. (PMID: 36280250) ; J Eval Clin Pract. 2017 Aug;23(4):860-865. (PMID: 28370742) ; Fam Pract. 2019 Oct 8;36(5):544-551. (PMID: 30629165) ; Rev Esp Geriatr Gerontol. 2015 Mar-Apr;50(2):89-96. (PMID: 25466971) ; Semergen. 2021 May-Jun;47(4):267-279. (PMID: 33223372) Contributed Indexing: Keywords: Community pharmacy; Drug Related Problem; Farmacia comunitaria; Inhibidor de la bomba de protones; Omeprazol; Omeprazole; Plataforma digital Revisem®; Problema relacionado con la medicación; Proton Pump Inhibitor; Revisem® digital platform Substance Nomenclature: 0 (Proton Pump Inhibitors) Entry Date(s): Date Created: 20231227 Date Completed: 20240428 Latest Revision: 20240614 Update Code: 20240615 PubMed Central ID: PMC11058877

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

[New tools for medication review: DRP in patients treatment with proton pump inhibitors].